- Home
- AFCG vs TCRX Comparison
AFCG vs TCRX Comparison
Compare AFCG & TCRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AFCG
- TCRX
- Stock Information
- Founded
- AFCG 2020
- TCRX 2018
- Country
- AFCG United States
- TCRX United States
- Employees
- AFCG N/A
- TCRX N/A
- Industry
- AFCG Real Estate Investment Trusts
- TCRX Biotechnology: Pharmaceutical Preparations
- Sector
- AFCG Real Estate
- TCRX Health Care
- Exchange
- AFCG Nasdaq
- TCRX Nasdaq
- Market Cap
- AFCG 113.0M
- TCRX 90.5M
- IPO Year
- AFCG 2021
- TCRX 2021
- Fundamental
- Price
- AFCG $5.50
- TCRX $1.38
- Analyst Decision
- AFCG Buy
- TCRX Strong Buy
- Analyst Count
- AFCG 7
- TCRX 7
- Target Price
- AFCG $11.00
- TCRX $9.86
- AVG Volume (30 Days)
- AFCG 144.3K
- TCRX 396.8K
- Earning Date
- AFCG 05-14-2025
- TCRX 05-06-2025
- Dividend Yield
- AFCG 23.93%
- TCRX N/A
- EPS Growth
- AFCG N/A
- TCRX N/A
- EPS
- AFCG 0.78
- TCRX N/A
- Revenue
- AFCG $41,494,025.00
- TCRX $4,421,000.00
- Revenue This Year
- AFCG N/A
- TCRX $47.30
- Revenue Next Year
- AFCG $23.25
- TCRX $74.30
- P/E Ratio
- AFCG $8.33
- TCRX N/A
- Revenue Growth
- AFCG N/A
- TCRX N/A
- 52 Week Low
- AFCG $4.34
- TCRX $1.02
- 52 Week High
- AFCG $10.88
- TCRX $9.69
- Technical
- Relative Strength Index (RSI)
- AFCG 48.49
- TCRX 42.86
- Support Level
- AFCG $5.27
- TCRX $1.32
- Resistance Level
- AFCG $5.87
- TCRX $1.65
- Average True Range (ATR)
- AFCG 0.24
- TCRX 0.13
- MACD
- AFCG 0.10
- TCRX -0.01
- Stochastic Oscillator
- AFCG 63.00
- TCRX 14.63
About AFCG AFC Gamma Inc.
Advanced Flower Capital Inc is a commercial mortgage REIT that provides institutional loans to cannabis operators in the U.S. Through the management team's deep network and related credit and cannabis expertise. The company originates, structures, and underwrites loans secured by quality real estate assets, license value, and cash flows.
About TCRX TScan Therapeutics Inc.
TScan Therapeutics Inc is a biopharmaceutical company focused on the development of T-cell receptor (TCR) engineered T cell therapies (TCR-T) for the treatment of patients with cancer. The company's liquid tumor TCR-T therapy candidates, TSC-100 and TSC-101, are in development for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell transplantation. It is also developing multiplexed TCR-T therapy candidates for the treatment of various solid tumors.